ADC Therapeutics: 'Strong Buy' With 2 Shots On Goal For ZYNLONTA In R/R DLBCL

ADC Therapeutics SA remains a Strong Buy, driven by pivotal ZYNLONTA combination trials targeting 2nd-line r/r DLBCL. Topline data from the phase 3 LOTIS-5 trial (ZYNLONTA + rituximab) is expected in Q2 2026, representing a major inflection point. ZYNLONTA + glofitamab in phase 1b LOTIS-7 achieved an 89.8% ORR and 77.6% CR rate, with further data expected by the end of 2026.